Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.

ABSTRACT: Despite substantial observational and experimental evidence that aspirin use can provide protection against the development of colorectal neoplasia, our understanding of the molecular mechanisms involved is inadequate and limits our ability to use this drug effectively and safely for chemoprevention. We employed an untargeted plasma metabolomics approach using liquid chromatography with high-resolution mass spectroscopy to explore novel metabolites that may contribute to the chemopreventive effects of aspirin. Associations between levels of metabolic features in plasma and aspirin treatment were investigated among 523 participants in a randomized placebo-controlled clinical trial of two doses of aspirin (81 or 325 mg/day) and were linked to risk of colorectal adenoma occurrence over 3 year

SUBMITTER: Barry EL 

PROVIDER: S-EPMC9357068 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature